Search Videos and More
Course
Stem Cell Transplant and Cellular Therapies Symposium 2026:
Navigating a Rapidly Changing Landscape
News
Dana-Farber Research News 08.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 16 - 31.
News
Collaborative Team Doubles Number of In Vitro Patient-Derived Cancer Models Available for Research
A collaborative team led by investigators from Dana-Farber Cancer Institute and elsewhere developed 665 next-generation patient-derived cancer models across 27 common and rare forms of cancer and made the models plus relevant clinical and molecular data available as a resource to researchers around the globe to accelerate cancer advances.
News
Dana-Farber Investigators Develop Protein Degrader Discovery Platform and Find First-in-Kind Metabolically Activated Molecular Glue Degrader
Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates. The platform could help drug developers dramatically expand the range of disease-related proteins that can be therapeutically targeted for elimination via protein degradation.
News
U.S. News & World Report Names Dana-Farber Brigham Cancer Center #1 Locally, #3 Nationally for 2026-2027
Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by U.S. News & World Report. This is the 26th consecutive year Dana-Farber Brigham has been recognized for its excellence in caring for people with cancer.
News
Dana-Farber Research News 08.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 1 - 15.
News
FDA Approves Personalized Blood-Test Guided Immunotherapy for Bladder Cancer, Backed by Dana-Farber Science
When patients with bladder cancer complete treatment that is intended to cure the cancer, they may be left wondering if there is anything else they should do to keep the cancer from coming back.
News
Dana-Farber Researchers Identify CDK8 as a Potential Therapeutic Target for Alveolar Rhabdomyosarcoma
Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma (aRMS), an aggressive childhood cancer with poor survival and few targeted treatment options, to identify new treatment vulnerabilities. Using a network-based analysis of large functional genomic datasets, they found that aRMS cells depend on CDK8, a protein involved in controlling gene activity.
News
Dana-Farber Research News 07.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 16 - 30.
News
Three-Drug Treatment Shows Promise for Patients with Rare Blood Cancer BPDCN
A three-drug treatment combination led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer, in a phase 2 clinical trial led by researchers at Dana-Farber Cancer Institute.
News
Dana-Farber Research Supports FDA Approval of New Therapy for “Double-Positive” Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute.
News
The RAS Moment for Pancreatic Cancer Research
Dana-Farber investigators are at the forefront of a new era in RAS therapeutics for pancreatic cancer research